Navigation Links
HPV testing: Indications of a benefit in primary screening
Date:1/24/2012

This release is available in German.

Studies currently available provide indications and a "hint" that precursors of cervical cancer can be detected and treated earlier, and consequently tumours occur less often, in women who underwent testing for human papillomavirus (HPV). In this context, an HPV test can be used alone or in addition to a Papanicolaou test (Pap smear). However, both screening procedures also carry a risk of harm in the form of unnecessary treatments after testing (over-treatment). This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 24th of January 2012.

HPV testing is not reimbursed by SHI funds

In screening for cervical cancer, the German statutory health insurance (SHI) funds currently offer an annual (cytologic) examination of mucosal cells from a smear taken from the neck of the womb (cervix). This test is called a Pap smear. Since it became known that infection with HPV is the main risk factor for developing cervical cancer, experts have been discussing whether HPV testing is also a suitable screening method or is even superior to a cytologic test.

The SHI funds currently only reimburse HPV testing in exceptional cases, for example, in cases where the result of a Pap smear is unclear. The Federal Joint Committee (G-BA) therefore commissioned IQWiG to assess the benefit of HPV testing in primary screening and also to compare different screening strategies with each other.

Lower rates of cancers and their precursors are independent outcome criteria

Cancer screening is usually assessed by determining whether this procedure demonstrably contributes to the prevention of cancer-related deaths. However, in cervical cancer the fact whether or not fully developed (invasive) tumours occur less often can also be a criterion for a screening benefit. Similar to the case of colon cancer, screening for cervical cancer aims to detect and treat cellular changes (dysplasia) from which a cancerous tumour could develop, as treatment of such (advanced) precursors of cancer is far less burdensome for patients than later treatment of a tumour.

Studies with a total of 235,613 participants included

IQWiG searched for studies comparing primary screening strategies for cervical cancer based on different screening tests: a strategy including HPV testing alone or in combination with cytology-based testing and a strategy including cytology-based testing alone.

Six randomized controlled trials conducted in the United Kingdom, Finland, Sweden, the Netherlands, and Italy were included in the assessment. A total of 235,613 women had been recruited for the studies in order to be examined for precursors of invasive cervical cancer in at least two screening rounds with an interval of at least three years. However, all of these studies were susceptible to bias, which limits their informative value.

Fewer cancer diagnoses in the second screening round

In the assessment IQWiG distinguished between different outcome criteria. The composite outcome "CIN3+" was analysed, which comprises both invasive cervical cancer and advanced precursors of cancer (high grade cervical intraepithelial dysplasia or in-situ cervical cancer, i.e. CIN3/CIS). In addition, the outcomes "invasive cervical cancer"- that is, not just the occurrence of a cancer precursor but of a tumour - as well as "CIN3/CIS" were analysed separately.

In the second screening round, the number of diagnoses for the two outcomes "CIN3+" and "invasive cervical cancer" was lower in the HPV group than in the group of women who had only been examined with a cytology-based screening strategy (e.g. Pap smear) in the first screening round. IQWiG therefore determined an indication of a benefit for these two outcomes.

If solely the advanced precursors of cancer are considered (CIN3/CIS), the data only provide a "hint" of a benefit. This is primarily due to a relatively large study that showed no difference between the HPV group and the comparator group. The new category "hint" expresses that certain minimum requirements for the available studies are fulfilled, but that conclusions on benefit and harm are only of low certainty.

No evaluable data on survival and quality of life

Conclusions on overall survival, mortality related to cervical cancer, and quality of life are not possible, as no data or no evaluable data were available for these outcomes.

Neither were evaluable data on potential screening-related harm available. For instance, unnecessary diagnostic procedures (e.g. biopsies) as a result of false-positive test results may harm patients. Moreover, the diagnosis itself can be a psychological burden, triggering anxieties or feelings of guilt.

Harm can also be caused by over-treatment. It is notable that women with moderate grade (CIN2) or sometimes even low grade cancer precursors were also treated in the included studies; in a great number of cases these precursors regress and only rarely progress into cancer. However, it cannot be estimated on the basis of these studies how often women who underwent HPV testing and/or a Pap smear were subjected to unnecessary treatment.

No recommendation for specific screening strategy possible

The complex screening strategies applied in the studies varied greatly and can therefore hardly be compared with each other. This applies to the participants' age and the intervals between follow-up examinations, as well as to the questions in which sequence or combination the HPV or cytology test should be applied and what measures should be undertaken after certain test results.

The study results therefore do not allow a recommendation for a specific screening strategy in the German health care system. The few common factors of the studies include the fact that the screening interval lasted at least three years and the screening programme was conducted in an organized population-based and quality assured context.


'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Early indications of Parkinsons disease revealed in dream sleep
2. Indications of Alzheimers disease may be evident decades before first signs of cognitive impairment
3. Prasugrel: Indications of an additional benefit for some patients, but also of greater harm
4. Children With Cerebral Palsy Benefitting From New Physical Therapy Regimen
5. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
6. Survival benefit with high-intensity end-of-life approaches
7. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
8. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
9. News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low
10. 1Dental.com Enhances Dental Plan Benefits With New Fee Schedule
11. AMERICAN IDOL to Benefit the UN Foundation Fund for Haiti Thursday, February 25, on FOX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology: